Alcidion Group Limited (ASX: ALC), a healthcare technology company operating across Australia, New Zealand, and the United Kingdom, has announced it will release its Appendix 4C Quarterly Cash Flow Report for the quarter ended 30 June 2026 on Thursday 23 July 2026. Alongside the report release, the company will host a live investor webcast at 11:00am AEST on the same day, where Group Managing Director and CEO Kate Quirke and CFO Matthew Gepp will present operational and commercial highlights from Q4 FY26. The webcast will include a Q&A session, giving investors an opportunity to engage directly with senior leadership. For investors tracking the company's progress in the competitive healthcare IT sector, the upcoming quarterly update represents a key moment to assess Alcidion's cash flow position and commercial momentum.

Key Points

  • Alcidion Group Limited (ASX: ALC) is a healthcare technology company headquartered in South Yarra, Victoria, Australia
  • Alcidion will release its Appendix 4C Quarterly Cash Flow Report for Q4 FY26 (quarter ended 30 June 2026) on Thursday 23 July 2026
  • A live investor webcast is scheduled for 11:00am AEST on 23 July 2026, hosted by CEO Kate Quirke and CFO Matthew Gepp
  • Investors are encouraged to submit questions in advance to [email protected] ahead of the live Q&A session

Alcidion's Appendix 4C Quarterly Cash Flow Report Scheduled for Release on 23 July 2026

Alcidion Group Limited has confirmed that its Appendix 4C Quarterly Cash Flow Report covering the quarter ended 30 June 2026 will be released to the market on Thursday 23 July 2026. The Appendix 4C is a mandatory quarterly reporting document required by the Australian Securities Exchange for listed entities below a certain threshold, providing shareholders and analysts with a transparent view of the company's cash receipts, cash payments, and overall liquidity position for the period.

For a software-focused healthcare technology business like Alcidion, the quarterly cash flow report is a closely watched indicator of operational health. Investors and analysts typically monitor metrics such as cash receipts from customers, staff and administration costs, and net operating cash flows to gauge whether the business is tracking toward sustainable cash flow generation. The company did not disclose specific financial figures for Q4 FY26 in this company update, as those details are reserved for the formal Appendix 4C release on 23 July 2026. The immediate share price impact of this notification was not clear from available public information.

CEO Kate Quirke and CFO Matthew Gepp to Present Q4 FY26 Operational and Commercial Highlights

The investor webcast scheduled for 11:00am AEST on Thursday 23 July 2026 will be led by Alcidion's Group Managing Director and CEO, Kate Quirke, alongside Chief Financial Officer Matthew Gepp. The two senior executives will walk investors through the operational and commercial highlights of the fourth quarter of FY26, offering context around the figures published in the Appendix 4C report. This format — pairing the formal financial document with a live management presentation — is designed to give investors qualitative insight alongside the quantitative data.

The inclusion of a Q&A session at the end of the webcast provides an additional layer of transparency, allowing registered participants to pose questions directly to Alcidion's senior leadership. Given that Alcidion operates in a specialised healthcare IT market across multiple geographies, investor questions are likely to span topics including contract pipeline updates, progress of the Miya Precision platform, and conditions across the UK and Australasian healthcare systems. Investors who wish to ask questions are encouraged by the company to submit them in advance to Alcidion's investor relations team at [email protected], due to time constraints during the live session.

How to Register for the Alcidion Q4 FY26 Investor Webcast via Zoom

Alcidion has confirmed that the Q4 FY26 investor webcast will be delivered via the Zoom webinar platform. Interested investors and market participants can register through the official Zoom registration link provided in the company update. Upon successful registration, participants will receive a confirmation email containing the Zoom access link and phone dial-in details, providing multiple ways to join the session regardless of location or device preference.

The webcast is open to all registered participants, including retail and institutional investors as well as market analysts and media. This approach to investor engagement reflects a broader trend among ASX-listed technology companies to deliver results presentations in a live, accessible digital format. For investors who are unable to attend the live session, it is common practice for companies to make recordings or transcripts available after the event, though Alcidion did not explicitly confirm this in the current company update. Investors are advised to monitor the company's official communications channels for any post-webcast materials.

Alcidion's Miya Precision Platform and Its Role in the Company's Healthcare IT Business

Alcidion's core commercial offering centres on its flagship product, Miya Precision, a clinical intelligence platform designed to aggregate meaningful patient information into centralised dashboards for use by healthcare professionals. The platform is built to support interoperability between disparate healthcare systems, facilitate communication and task management in clinical and operational settings, and deliver clinical decision support at the point of care. These capabilities are directly aligned with the priorities of modern hospital and healthcare organisations seeking to reduce clinical risk and improve patient outcomes through technology.

Miya Precision sits at the heart of Alcidion's complementary suite of software products and technical services, which together constitute the company's value proposition in the global healthcare technology market. The company's revenue model is based on software licensing and recurring services delivered to hospitals and healthcare organisations, a structure that typically generates predictable, subscription-style cash flows over multi-year contracts. The company's Q4 FY26 Appendix 4C will provide the market with a clearer picture of how this revenue model performed during the quarter, including the level of customer receipts generated by the Miya Precision ecosystem during the period to 30 June 2026.

Alcidion's Three-Market Operating Footprint Across Australia, New Zealand, and the United Kingdom

Since listing on the ASX in 2016, Alcidion has grown its operational footprint through a strategy of organic growth and targeted acquisitions of healthcare IT companies. The company now operates across three established geographic markets: Australia, New Zealand, and the United Kingdom. Each of these markets presents distinct healthcare system structures, regulatory environments, and technology procurement cycles, requiring Alcidion to maintain localised commercial and implementation capabilities alongside its core product development function.

The United Kingdom market, in particular, represents a significant opportunity for Alcidion given the scale of the National Health Service and its ongoing investment in digital health infrastructure. Operating in multiple international markets also introduces currency risk and the complexity of managing cross-border operations, which are factors investors may wish to consider when evaluating the company's quarterly cash flow results. The company has indicated that further geographical expansion beyond its current three markets is planned, although no specific new markets or timelines were disclosed in this company update. Alcidion's multi-market operating structure is a key distinguishing feature relative to purely domestic Australian healthcare IT peers.

Alcidion's 25-Year Healthcare Technology History and Growth Through Acquisitions

Alcidion brings more than 25 years of experience in the healthcare technology sector, a heritage that underpins its deep understanding of clinical workflows, hospital operations, and the regulatory requirements governing health IT systems in its operating markets. This accumulated domain expertise is a critical competitive asset, particularly in a sector where trust, clinical credibility, and long implementation cycles mean that relationships between technology vendors and healthcare organisations tend to be deeply embedded and long-term in nature.

The company's growth strategy has included the acquisition of multiple healthcare IT businesses since its ASX listing in 2016, each of which has contributed additional products, customer relationships, or geographic reach to the overall group. This acquisition-led growth model has shaped Alcidion's current portfolio of complementary software products and technical services, and it has also been a factor in the company's cash flow profile over various periods. Investors reviewing the upcoming Q4 FY26 Appendix 4C will be able to assess how the integrated business is performing from a cash generation perspective as it continues to execute on its stated mission of transforming healthcare through proactive, smart, and intuitive technology solutions.

Sector Drivers Supporting Demand for Alcidion's Clinical Decision Support Technology

The healthcare technology sector is being driven by a number of powerful structural forces that are supportive of demand for solutions like those offered by Alcidion. Ageing populations across Australia, New Zealand, and the United Kingdom are placing sustained pressure on hospital systems, increasing the urgency for technology solutions that can improve efficiency and reduce avoidable clinical errors. Governments and health authorities in all three of Alcidion's operating markets have committed to digital health transformation programs, creating funded procurement activity for clinical intelligence and decision support platforms.

Interoperability — the ability of different healthcare IT systems to share and use patient data seamlessly — has emerged as a central policy priority for health system administrators, and it is one of the core capabilities built into Alcidion's Miya Precision platform. This alignment between product capability and systemic policy need positions Alcidion favourably in competitive tender processes for large hospital and health network contracts. The Q4 FY26 results and webcast will offer investors a timely read on how effectively the company is converting this favourable demand environment into contracted revenue and cash receipts during the most recent quarter.

Company-Specific Risks Investors Should Consider Ahead of the Q4 FY26 Results

While Alcidion operates in a sector with strong structural tailwinds, the company faces a number of specific risks that investors should consider ahead of the Q4 FY26 Appendix 4C release. Healthcare IT procurement in public hospital systems is often subject to lengthy decision-making cycles, budget constraints, and political factors that can delay or defer contract signings and implementation timelines. Any slippage in expected contract commencements could affect cash receipts in a given quarter, making the Appendix 4C a sensitive disclosure for market participants tracking commercial momentum.

Operating across three international markets also exposes Alcidion to foreign currency movements, particularly fluctuations in the British pound relative to the Australian dollar, which can affect the translated value of UK revenues and costs. The company's growth-through-acquisition strategy, while a source of capability expansion, introduces integration risk and can create complexity in managing a diverse product portfolio across different technical architectures. Investors may also consider the competitive dynamics of the healthcare IT market, where Alcidion competes against both global enterprise software vendors and specialised regional players. These risks do not diminish the company's market position but are relevant context for interpreting the quarterly results.

What the 23 July 2026 Quarterly Update Means for Investors Watching Alcidion's Progress

The release of the Q4 FY26 Appendix 4C on 23 July 2026, combined with the live investor webcast on the same morning, represents the next major information event for Alcidion shareholders and prospective investors. The fourth quarter of a financial year is typically significant for software businesses because it often captures the outcome of sales and renewal cycles that close before financial year-end, meaning Q4 cash receipts can be a telling indicator of annual commercial performance and pipeline conversion.

Investors may be watching for commentary from CEO Kate Quirke and CFO Matthew Gepp on the state of the company's contract pipeline, the trajectory of recurring revenue from existing customers, and any updates on expansion plans into new geographies. The Q&A component of the webcast provides an additional opportunity for the market to probe management on topics that matter most to shareholders. The combination of the formal Appendix 4C figures and the management webcast discussion is likely to shape near-term market sentiment around Alcidion's FY26 full-year performance and its outlook heading into FY27.